HK Stock Market Move | JACOBIO-B (01167) has risen over 11%, and institutions are optimistic about JAB-23E73 as a potential heavyweight asset.

JACOBIO-B (01167) rose over 11%, and as of the time of writing, it is up 8.61%, at HKD 6.625, with a trading volume of HKD 31.6831 million. On the news front, JAKS's revenue for the first half of the year was HKD 731 million, an increase of 1500.5% year-on-year; the profit attributable to the companys owners was HKD 601 million, turning a profit compared to a loss in the previous year. The revenue growth was mainly due to the strategic collaboration with AstraZeneca AB for the global R&D, production, and commercialization of JAB-23E73; and the external licensing and service agreements signed with Shanghai Allist Pharmaceuticals Co., Ltd. for the R&D, production, and commercialization of Arecap and sitneprotafib. CMB International released a research report stating that JAKS's core investment logic is continuously strengthened with the latest clinical data readouts of JAB-23E73 (pan-KRAS). The updated data further verifies the excellent anti-tumor activity and good tolerance of this drug, and we believe this gives it a significant differentiated advantage in the pan-KRAS space. With its first-mover position, clear intellectual property pathway, and production advantages in small molecule drugs, we view JAB-23E73 as a potential blockbuster asset.